<?xml version="1.0" ?>
<document id="8147b5b09a09887d1b4c4871d9d49746d8c4d418">
  <chunk id="8147b5b09a09887d1b4c4871d9d49746d8c4d418.c0" text="A Multiple Antigenic Peptide Mimicking Peptidoglycan Induced T Cell Responses to Protect Mice from Systemic Infection with Staphylococcus aureus">
    <entity charOffset="21-28" id="8147b5b09a09887d1b4c4871d9d49746d8c4d418.c0.e0" ontology_id="CHEBI_16670" text="Peptide" type="chemical"/>
    <entity charOffset="39-52" id="8147b5b09a09887d1b4c4871d9d49746d8c4d418.c0.e1" ontology_id="CHEBI_8005" text="Peptidoglycan" type="chemical"/>
  </chunk>
  <chunk id="8147b5b09a09887d1b4c4871d9d49746d8c4d418.c1" text="Due to the enormous capacity of Staphylococcus aureus to acquire antibiotic resistance, it becomes imperative to develop vaccines for decreasing the risk of its life-threatening infections. Peptidoglycan (PGN) is a conserved and major component of S. aureus cell wall. However, it has not been used as a vaccine candidate since it is a thymus-independent antigen. In this study, we synthesized a multiple antigenic peptide, named MAP27, which comprised four copies of a peptide that mimics the epitope of PGN. After immunization with MAP27 five times and boosting with heat-inactivated bacterium one time, anti-MAP27 serum bound directly to S. aureus or PGN. Immunization with MAP27 decreased the bacterial burden in organs of BALB/c mice and significantly prolonged their survival time after S. aureus lethal-challenge. The percentage of IFN-γ + CD3 + T cells and IL-17 + CD4 + T cells in spleen, as well as the levels of IFN-γ, IL-17A/F and CCL3 in spleen and lung, significantly increased in the MAP27-immunized mice after infection. Moreover, in vitro incubation of heat-inactivated S. aureus with splenocytes isolated from MAP27-immunized mice stimulated the production of IFN-γ and IL-17A/F. Our findings demonstrated that MAP27, as a thymus-dependent antigen, is efficient at eliciting T cell-mediated responses to protect mice from S. aureus infection. This study sheds light on a possible strategy to design vaccines against S. aureus.">
    <entity charOffset="65-75" id="8147b5b09a09887d1b4c4871d9d49746d8c4d418.c1.e0" ontology_id="CHEBI_33281" text="antibiotic" type="chemical"/>
    <entity charOffset="190-203" id="8147b5b09a09887d1b4c4871d9d49746d8c4d418.c1.e1" ontology_id="CHEBI_8005" text="Peptidoglycan" type="chemical"/>
    <entity charOffset="415-422" id="8147b5b09a09887d1b4c4871d9d49746d8c4d418.c1.e2" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
    <entity charOffset="470-477" id="8147b5b09a09887d1b4c4871d9d49746d8c4d418.c1.e3" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
    <entity charOffset="494-501" id="8147b5b09a09887d1b4c4871d9d49746d8c4d418.c1.e4" ontology_id="CHEBI_53000" text="epitope" type="chemical"/>
    <entity charOffset="1378-1383" id="8147b5b09a09887d1b4c4871d9d49746d8c4d418.c1.e5" ontology_id="CHEBI_30212" text="light" type="chemical"/>
  </chunk>
</document>
